ResMed Inc. (RMD): Price and Financial Metrics
ResMed Inc. (RMD)
Today's Latest Price: $221.32 USD
Updated Jan 25 3:27pm
Add RMD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 186 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
RMD Stock Summary
- Resmed Inc's market capitalization of $31,232,113,775 is ahead of 92.36% of US-listed equities.
- Price to trailing twelve month operating cash flow for RMD is currently 39.84, higher than 87.89% of US stocks with positive operating cash flow.
- With a price/sales ratio of 10.31, Resmed Inc has a higher such ratio than 83.03% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Resmed Inc are A, CSGP, CERN, EBAY, and BAX.
- Visit RMD's SEC page to see the company's official filings. To visit the company's web site, go to www.resmed.com.
RMD Stock Price Chart Interactive Chart >
RMD Price/Volume Stats
| Current price | $221.32 | 52-week high | $224.24 |
| Prev. close | $215.52 | 52-week low | $108.85 |
| Day low | $215.73 | Volume | 330,850 |
| Day high | $224.00 | Avg. volume | 430,662 |
| 50-day MA | $212.44 | Dividend yield | 0.72% |
| 200-day MA | $186.07 | Market Cap | 32.07B |
ResMed Inc. (RMD) Company Bio
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing. The company was founded in 1989 and is based in San Diego, California.
RMD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $221.32 | $67.43 | -69% |
Below please find a table outlining a discounted cash flow forecast for RMD, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Resmed Inc ranked in the 26th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 68.5%. The most interesting components of our discounted cash flow analysis for Resmed Inc ended up being:
- The company's debt burden, as measured by earnings divided by interest payments, is 23.04; that's higher than 86.26% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately just 14.38% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- RMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 45.55% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -69% |
| 1% | -69% |
| 2% | -69% |
| 3% | -68% |
| 4% | -68% |
| 5% | -68% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RMD, try ABT, AZN, ABC, CPIX, and HSIC.
Loading social stream, please wait...